Brought to you by 
Tesaro nets $409mm through public offering
22 Jul 2016
Executive Summary
Tesaro Inc. (oncology therapies) publicly sold 5.35mm common shares (including the overallotment) at $81 for net proceeds of $409mm. Some of the money will fund commercialization of Varubi (rolapitant) and rolapitant IV, both indicated for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. Proceeds will also support ongoing trials for niraparib (in Phase III for ovarian and breast cancers) and additional immuno-oncology projects in the company's pipeline.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tesaro nets $409mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice